Novartis CEO: Deals possible in diagnostics, vaccines

Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a robust pipeline of new therapies will lead the drug giant to better days. In an interview with the Swiss weekly Sonntag, Vasella said Novartis' recent deal to buy a stake in Alcon for $11 billion represented a move to diversify the business. And more deals may lie ahead.

"Medium-sized acquisitions, which are not planned at the moment, would certainly still be possible," Vasella told the pub. "Diagnostics is a business field worth expanding, so are vaccines and generics."

Alcon, meanwhile, plans to build a manufacturing facility in Singapore to supply pharmaceuticals to the Asian market. Singapore has been swiftly growing as a manufacturing hub for the region.

- read the AFX report

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.